We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
Cap. Flow
-$176M
Cap. Flow %
-4.93%
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
PCVX icon
Vaxcyte
PCVX
+$45.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$38.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$158M
2
RLMD icon
Relmada Therapeutics
RLMD
+$88.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$43.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.4M
5
EW icon
Edwards Lifesciences
EW
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Financials 0.08%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGC
76
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.77M 0.11%
1,500,000
– –
TYRA icon
77
Tyra Biosciences
TYRA
$1.59B
$3.76M 0.11%
494,403
– –
PNT
78
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.65M 0.1%
500,000
– –
CYPH
79
Cypherpunk Technologies Inc
CYPH
$177M
$3.03M 0.09%
672,650
-74,565
-10% -$499K
CABA icon
80
Cabaletta Bio
CABA
$546M
$2.94M 0.08%
+317,454
New +$1.16M
KRON
81
DELISTED
Kronos Bio
KRON
$2.84M 0.08%
1,752,745
-403,406
-19% -$929K
PRCT icon
82
Procept Biorobotics
PRCT
$1.24B
$2.68M 0.08%
64,537
-199,183
-76% -$8.55M
IMVT icon
83
Immunovant
IMVT
$8.99B
$2.66M 0.07%
+150,000
New +$1.89M
ATNX
84
DELISTED
Athenex, Inc. Common Stock
ATNX
$2.29M 0.06%
776,623
– –
PRVA icon
85
Privia Health
PRVA
$2.71B
$2.04M 0.06%
+90,000
New +$2.51M
TVTX icon
86
Travere Therapeutics
TVTX
$6.32B
$1.91M 0.05%
90,748
– –
ABOS icon
87
Acumen Pharmaceuticals
ABOS
$224M
$1.88M 0.05%
347,450
-52,550
-13% -$353K
DRIO icon
88
DarioHealth
DRIO
$72.4M
$1.4M 0.04%
16,393
– –
CLOV icon
89
Clover Health Investments
CLOV
$2.19B
$1.39M 0.04%
1,500,000
– –
NVRO
90
DELISTED
NEVRO CORP.
NVRO
$1.19M 0.03%
30,000
-120,000
-80% -$4.99M
PEAR
91
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$1.06M 0.03%
900,548
– –
TARA icon
92
Protara Therapeutics
TARA
$235M
$777K 0.02%
290,051
– –
MOTS
93
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$75.6K ﹤0.01%
6,002
– –
EQRXW
94
DELISTED
EQRx, Inc. Warrant
EQRXW
$67K ﹤0.01%
250,000
– –
CMAXW
95
DELISTED
CareMax, Inc. Warrant
CMAXW
$31.3K ﹤0.01%
60,000
– –
SRZNW
96
DELISTED
Surrozen Inc Warrant
SRZNW
$9.18K ﹤0.01%
166,666
– –
ABSI icon
97
Absci
ABSI
$1.65B
– –
-894,346
Closed -$2.8M
APLS
98
DELISTED
Apellis Pharmaceuticals
APLS
– –
-366,400
Closed -$25M
CCCC icon
99
C4 Therapeutics
CCCC
$517M
– –
-766,231
Closed -$6.72M
CHRS icon
100
Coherus Oncology
CHRS
$212M
– –
-1,667,123
Closed -$16M
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $176M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.

  • Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
  • Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
  • Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
  • Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
  • Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.